Volume 9, Number 1—January 2003
Perspective
Maintaining Fluoroquinolone Class Efficacy: Review of Influencing Factors
Table 4
Clinical failures of Streptococcus pneumoniae infection with levofloxacina
Risk factors | ||||||||
---|---|---|---|---|---|---|---|---|
No. of cases |
Age |
Indication |
Coexisting conditions |
Prior FQ use |
Yr |
Ref. |
Country |
|
1b |
58 |
Meningitis |
HIV, splenectomy |
NR |
1999 |
62 |
USA |
|
3 |
NR |
RTI |
Yes |
1999 |
63 |
USA |
||
1 |
63 |
CAP |
COPD |
No |
1999 |
64 |
USA |
|
1 |
50 |
CAP |
COPD |
No |
2000 |
65 |
USA |
|
1 |
84 |
CAP |
COPD |
Yes-Levo |
2000 |
65 |
USA |
|
1 |
53 |
HAP |
none |
No |
2001 |
66 |
USA |
|
7 |
39-83
(avg. 63) |
4 CAP
3 AECB |
COPD (5) |
5/7
(4-Lev, 1-Mox) |
2001 |
67 |
USA |
|
1 |
37 |
CAP |
none |
No |
1999 |
25 |
Canada |
|
1b |
66 |
CAP |
COPD |
Yes-Cip +
Lev |
1999 |
25 |
Canada |
|
1 |
80 |
AECB/CAP |
COPD, |
Yes-Cip |
2001 |
25 |
Canada |
|
1 |
64 |
CAP |
none |
No |
2000 |
25 |
Canada |
|
1 |
50 |
CAP |
COPD |
Yes-Lev |
2001 |
68 |
USA |
|
1b |
79 |
CAP |
none |
NO |
1999 |
69 |
USA |
|
21 |
||||||||
Clinical trials |
||||||||
13 (7 on 500 mg) |
NR |
AECB |
COPD |
No |
70 |
Neth. |
||
4 |
NR |
CAP |
NR |
No |
71 |
USA |
||
24 (11) |
||||||||
Epidemiologic studies |
||||||||
16c |
- |
LRTI |
COPD |
Yes-Cip |
1995-96 |
72 |
Canada |
|
27d |
- |
LRTI |
COPD (17) |
Yes-Lev |
1998-99 |
73 |
HK |
|
43 |
||||||||
Total | 88 (74 on 500 mg) clinical/bacteriologic failures |
aFQ, fluoroquinolone; NR, not reported; RTI, respiratory tract infection; CAP, community-acquired pneumonia; COPD, chronic obstructive pulmonary disease; Lev, levofloxacin; Mox, moxifloxacin; HAP, hospital-acquired pneumonia; AECB, acute exacerbation of chronic bronchitis;
LRTI, lower respiratory tract infection; Cip, ciprofloxacin; Neth, the Netherlands; HK, Hong Kong.
bDeath.
c3 deaths.
d4 deaths.